Louis Chênevert Business Legacy that still lives on

Companies need big leaders to achieve success and that is what Louis Chênevert has been all about through out career. He has had a distinguished career that has seen him work for different companies and achieving a lot of success at each stage. His brings a wealth of experience and knowledge of business at every turn.

Louis Chênevert is the immediate former CEO of United Technologies Corporation (UTC). He joined the company in 2006 and has served in various capacities during his tenure. He managed to transform the company into one of the best performing in the industry. His tenure was marked by massive investments on various businesses’ operations including employee training through the Employee Scholar Program.

United Technologies Corporation (UTC) specializes in assembling jet engines, helicopter systems, air conditioning and refrigeration systems. Louis Chênevert oversaw one of the company’s major milestones and that was the development of the Geared Turbofan which went into the history of the aerospace industry as a major advancement. His willingness to invest in the company’s technologies proved crucial in driving the future growth of UTC. Louis’s legacy at the Connecticut based company still lives on as the company continues to be the leading manufacturer of aerospace products.

He previously worked for General Motors as a Production General Manager. His achievement at the company during his 14 years was sealing a deal with Goodrich worth $18.4 billion. He also worked for Pratt & Whitney both in the capacity of the Vice-president of operation and the president. After leaving UTC in 2014, Louis proceeded to work for Goldman Sachs’s Merchant Banking Division as an Executives adviser up until 2017. His role included scouting for business opportunities in the industrial and aerospace industries.

Chênevert also serves in various committees including Chairman of the Yale Cancer Centre, Business Council, Board of directors of Cargill Inc., and Chairman of the Congressional Medal of Honor Foundation.

He graduated from the University of Montreal, School of Business with a degree in production management. He also holds two doctorate honoris causa from HEC Montreal and Concordia University respectively. He was also awarded the 2009 Honor award by the National Building Museum.

http://www.courant.com/business/hc-goldman-sachs-louis-chenevert-20150909-story.html

Proteostasis Is Not Looking So Hot After Sahm Adrangi’s Statements In Kerrisdale Report

Not all companies out there are worth investing in and Sahm Adrangi is one of the top investors in the country today that is doing his duty to inform other investors and the general public of companies that are an issue. The latest company that has taken fire from Kerrisdale Capital, Sahm Adrangi’s investment company, is Proteostasis. This biotech firm has made claims recently that they have had great success developing a new drug for cystic fibrosis patients. So far, Proteostasis claims this drug will dramatically increase lung performance for patients.

In order to get to the bottom of whether or not these claims are good, Sahm Adrangi and Kerrisdale has done some digging into the biotech firm. Unfortunately, what Sahm has found is not so good for those who might be excited about this new drug. CFTR amplifier PTI-428 is what Proteostasis is calling their product, which Sahm is calling a drug cocktail. According to the report, Proteostasis only had four subjects for their testing, which means this was a very small scale test that cannot be accurately assessed based on the presented data. Not only is the data incomplete, but the results are messy and practically missing, which causes Sahm Adrangi to believe these statements are likely false or due to very poor testing procedures by the biotech company. The placebo test conducted found a drop in lung performance as well, meaning their statements that this drug can increase lung performance cannot be true.

Due to all of these concerns, Kerrisdale has taken the short position with Proteostasis. This means they will continue to profit as the stock value of Proteostasis drops, which it has already started doing since Kerrisdale’s negative report went public. This is mostly because of other investors that are keen to follow the advice of Sahm Adrangi, who happens to be a high-profile investor in the U.S. that regularly states his opinions on companies and calls them out for their shady practices. Sahm has an impressive track record of success, couple that with hardly being wrong in his investments or arguments, most investors have started following in his footsteps.

https://www.cnbc.com/2016/05/05/short-seller-kerrisdale-to-target-dish-network.html

Volatility of the Market is Discussed by Shervin Pishevar

Shervin Pishevar is an Iranian-American entrepreneur, venture capitalist, and super angel investor. He is the co-founder and former executive chairman of Hyperloop One and a co-founder and managing director of Sherpa Capital, a venture capital fund which has invested in companies including Airbnb, Uber, and Munchery.

There is a significant amount of market volatility and more is likely to come according to Shervin Pishevar. Shervin is a venture capitalist who has become an early investor for a large number of tech companies. He has the ability to track trends early on, which has led to his success.

Recently, he sent out 50 tweets, all numbered, within 21 hours. Throughout these tweets, he talked about the market volatility and what would likely happen.

What is going on with market volatility?

On the second tweet of his tweet storm, Shervin Pishevar identified that the market has already given up all of the gains that it made in 2018. He says that the gains from 2017 will also be given up.

With the gains being given up, there will also be a rise in interest rates and an increase in credit account deficits. Further, various asset classes are likely to be overvalued.

What could happen with the market?

Throughout tweets seven through twelve, Shervin Pishevar makes a few predictions. This includes identifying indices as becoming more volatile. He goes on to say that whenever a market tanks, a managed future fund usually gets taken out.

All of the information that he shares throughout the tweets has been explored in one way or another by his followers. Some agree with what he has to say while others are providing their own insight into the market. Shervin Pishevar feels that the bond market will be the first to rally and if the market doesn’t normalize, hints of QE4 will likely be seen from leaders.

The stock market hasn’t crashed, yet it is certainly losing its gains. Within a day of Shervin’s posts, the market was losing more points than usual. His first tweet says it all – he believes 6,000 points will be lost within the next several months.

Visit This Page to learn more.

Shervin Pishevar Goes On Twenty-One Hour Tweet Storm: Here Is Why You Should Care

When Shervin Pishevar went on a twenty-one-hour tweet storm recently, a lot of people were paying attention. They were hanging on his every word through the fifty or so tweets that he sent out during that period of time. This is because Shervin Pishevar was talking about topics like the economy, modern technology, and even Bitcoin. He was giving his opinions on each, and it was well worth the read.

 

For those who don’t know, Shervin Pishevar was an early investor in the likes of Uber and Airbnb. He had the foresight to see that those companies were going to be great before the vast majority of us had paid any attention to them or even knew what they were. Many would say that this puts Shervin Pishevar in a league all on his own.

 

Pishevar seemed to have perfect timing on this as just one day after his Twitter storm, the markets took a big nosedive. At one point during that wild trading day, the Dow Jones Industrial Average lost approximately 500 points in just about a half hour. Pishevar quickly labeled this the “#TrumpDump”.

 

There were definitely some controversial tweets in the mix. For example, when Pishevar called for a six thousand point drop in the Dow Jones people started to take notice. This was just the first of numerous tweets that Pishevar was to put out on a day that was full of activity. It caught people’s attention both for the tremendous drop in the market that it predicted, but also because Pishevar had not tweeted in a while.

 

Many more tweets followed that described why Pishevar believed that the market would take on such a decline. He went on to explain that inflation was likely to be a big driver of the markets in the United States. He predicted that inflation will rise, and that this will cause the markets to fall in tandem.

 

There was plenty of interesting material in the tweet storm to be sure. It was so broad ranging that there is something in there for just about anyone. Interesting topics were covered by a very interesting person, and that is worth all of our attention. Find Additional Information Here.

Sahm Adrangi Bets Against Bad Medicine

Investment banking usually means hoping for the success of a business you are investing in, but for hedge fund investor Sahm Adrangi nothing could be further from the case. Sahm Adrangi is one of the new types of investors that practice activist investment, a type of investing based on personal values. Typically Adrangi focuses his energy on certain industries where he has obtained a sort of expertise and lately his focus has been on the biotech industry.

 

Within weeks of each other in 2017, two companies saw their heavily promoted drugs fail completely during Phase III trials. Sam Adrangi foresaw this outcome at least a year before each and had presented his research through various media to the let the world know his findings.

 

Prostvac, a drug in development to vaccinate against prostate cancer that was being developed by Bavarian Nordic, had already received $60 million in licensing from Bristol-Myers Squibb with $80 million at the ready upon conclusion of Phase III testing. Upon failure in testing, Bavarian Nordic saw their shares’ value drop by half. Sahm Adrangi had predicted this failure in 2015 and had led a very successful short selling attack on the company to discourage them from pushing the drug and incidentally profit when they chose to continue with testing the doomed medication.

 

The second medication was to real a form of epilepsy and was being developed by Sage Therapeutics. The initial test groups for Phase I and II trials were extremely small, meaning the statistics for success were more likely to be inaccurate. At the completion of Phase III, it was shown that the response rate was only 43.9% compared to the 42.4% rate in placebo. This 1.4% variance led to yet another successful short selling attack by Sahm Adrangi that began in 2016. View Related Info Here.

 

Sahm Adrangi is a Yale graduate and the Chief Investment Officer of Kerrisdale Capital Management LLC, a New York-based boutique investment firm that he also founded in 2009 with less only around one million dollars. Throughout the company’s existence, they have managed hundreds of millions of dollars and are known around the world for their bets against bad business.